Related references
Note: Only part of the references are listed.Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
Lucine Marotte et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Programmed Cell Death-1/ Ligand-1 PET Imaging A Novel Tool to Optimize Immunotherapy?
Sarah R. Verhoeff et al.
PET CLINICS (2020)
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
Konrad Pawelczyk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Omid Hamid et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
Kevin J. H. Allen et al.
PHARMACEUTICS (2019)
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition
Yilun Wu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Development of Targeted Alpha Therapy from Bench to Bedside
Alfred Morgenstern et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES (2019)
Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials
Loredana Marcu et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Avelumab: a new standard for treating metastatic Merkel cell carcinoma
Mairead Baker et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
Jamaal A. Rehman et al.
MODERN PATHOLOGY (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma
Masahiro Kikuchi et al.
ONCOIMMUNOLOGY (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
Joel C. Sunshine et al.
CLINICAL CANCER RESEARCH (2017)
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Harriet M. Kluger et al.
CLINICAL CANCER RESEARCH (2017)
Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer
Anders Josefsson et al.
CANCER RESEARCH (2016)
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
Chun-Te Wu et al.
SCIENTIFIC REPORTS (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Molecular Pathways: Targeted α-Particle Radiation Therapy
Kwamena E. Baidoo et al.
CLINICAL CANCER RESEARCH (2013)
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma
Michel Cherel et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
Caroline Bodet-Milin et al.
FRONTIERS IN ONCOLOGY (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
Barry J. Allen et al.
IMMUNOTHERAPY (2011)
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Chuan-Yong Mu et al.
MEDICAL ONCOLOGY (2011)
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
Yael S. Barach et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
George Sgouros et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Qiang Gao et al.
CLINICAL CANCER RESEARCH (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Interim analysis of oxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
Chand Raja et al.
CANCER BIOLOGY & THERAPY (2007)
Intralesional targeted alpha therapy for metastatic melanoma
BJ Allen et al.
CANCER BIOLOGY & THERAPY (2005)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)